GoldenGolden
Advanced Search
Arvinas

Arvinas

A pharmaceutical company developing protein degradation drugs to treat cancer and other diseases

Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins.

Timeline

April 2018
Arvinas raises a $55,000,000 series C round from Deerfield Management Company, Hillhouse Capital Group, Nextech Invest and Sirona Capital.
October 2015
Arvinas raises a $41,600,000 series B round from 5AM Ventures, Canaan Partners, New Leaf Venture Partners, OrbiMed and RA Capital Management.
2014
Arvinas was founded by Craig M. Crews.
September 26, 2013
Arvinas raises a $15,000,000 series A round from 5AM Ventures, Canaan Partners and Connecticut Innovations.

Funding rounds

People

Name
Role
LinkedIn

Manny Litchman

Employee

Further reading

Title
Author
Link
Type
Date

Case study on Arvinas

Axial

Web

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Nick Paul
August 18, 2021
FierceBiotech
Add another biotech to the list of protein degrader startups. Weeks after Pfizer's landmark deal with Arvinas, Sino-American biotech Ranok Therapeutics has unveiled a $40 million series B round to fund work on a cancer program.
Amirah Al Idrus
July 22, 2021
FierceBiotech
Pfizer is doubling down on Arvinas. Three years after the duo inked a discovery and development deal, they're adding commercialization to the mix. Pfizer is forking over $650 million upfront and investing $350 million in Arvinas to develop and commercialize the latter's protein-degrading breast cancer drug.
Amirah Al Idrus
December 14, 2020
FierceBiotech
Just in time for the holiday season, Arvinas' lead protein degraders delivered promising early results in patients with hard-to-treat breast or prostate cancer. As the company continues those phase 1 trials, it's gearing up for new trials in 2021, including dose-expansion and combination studies.
BioSpace
June 11, 2020
BioSpace
Arvinas, Inc., a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, announced that Linda Bain has joined its Board of Directors.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.